Arthneeti

IOL Chemicals & Pharmaceuticals Q1 FY27 Share Price & Earnings Call Analysis

₹184.93+2.39% today
Market cap
₹5,428 Cr
P/E
30.74
ROE
8.42%
PEG
20.50
Price to sales
2.15
Debt to equity
0.08
52W high / low
₹220 / ₹68.2
Sales growth (5Y)
3.35%
EBITDA margin
12.30%
Net profit margin
6.32%
Promoter holding
62.28%
Sales (last year)
₹2,524 Cr

IOL Chemicals & Pharmaceuticals Ltd is a leading pharmaceutical (APIs) company and is a significant player in the specialty chemicals space. It serves the domestic and export market.[1]

Guidance scorecard · Q1 FY27 call

What IOL Chemicals's management guided
and where it ranks in Pharmaceuticals & Biotechnology

#71of 83 in
Pharmaceuticals & Biotechnology
Revenue10–20%MarginsFlatCapexPlannedFundraisingWhat management saidOrder bookRising

RevenueQ1 FY27 call

10–20%
  • For FY27, the company expects revenue growth of 15% to 20% with EBITDA margin between 14% to 15%.
  • Growth is driven by higher capacity utilization, better product mix, operational efficiencies, and strong demand in domestic and export markets.
  • For FY28, a similar growth rate of 15% to 20% in top line and 15% to 17% EBITDA margin is targeted, subject to market conditions.
  • Sustainable growth is supported by a diversified and broad-based product portfolio expanding beyond ibuprofen.
  • Export contribution is targeted around 25% to 30% of revenue, with potential to move toward 30%+.

2 more points from IOL Chemicals's call on revenue

Create a free account to keep reading this call

Full Q1 FY27 analysis

MarginsQ1 FY27 call

Flat

See what IOL Chemicals said on margins — free account, 30 seconds.

Full Q1 FY27 analysis

CapexQ1 FY27 call

Planned
  • IOL plans a capex of approximately INR 200-250 crores annually, with around 60% directed toward expansion and new product development, and 40% toward infrastructure and efficiency improvements.
  • The company has a 101-acre land parcel for future expansion, with statutory permissions underway.
  • Major new projects on this land are not expected to be commissioned within the current fiscal year (FY27); likely FY28 or FY29 growth platforms.
  • IOL is actively working on R&D initiatives, with investments in advanced analytical equipment (XRD, LCMS, GCMS) to support product development.

2 more points from IOL Chemicals's call on capex

Create a free account to keep reading this call

Full Q1 FY27 analysis

FundraisingQ1 FY27 call

See what IOL Chemicals said on fundraising — free account, 30 seconds.

Full Q1 FY27 analysis

Order bookQ1 FY27 call

Rising
  • IOL Chemicals and Pharmaceuticals Limited has reasonable visibility into their order book for the coming quarter as of Q1 FY27.
  • The company expects sustained demand based on this order book visibility, supporting their confident revenue growth guidance.
  • They anticipate revenue growth of around 15% to 20% with EBITDA margins around 14% to 15% for FY27, indicating a healthy order inflow.

2 more points from IOL Chemicals's call on the order book

Create a free account to keep reading this call

Full Q1 FY27 analysis
Full Pharmaceuticals & Biotechnology ranking

Ranges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.

Potential multibaggers · Q2 FY27

Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance

  1. Strong growth
    2
  2. Strong growth
    1
  3. Strong growth
    3
See all potential multibaggersWhere does IOL Chemicals rank?

Portfolio builder

Build your portfolio
from the top-ranked stocks

  1. 1. Pick 3–15 stocks
  2. 2. Choose large, mid or small cap and your sectors
  3. 3. Get a portfolio built from the rankings
Build my portfolio

Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.

Peers

Pharmaceuticals & Biotechnology companies ranked on guidance

#CompanyRevenue guidedMargin guidedMarket capP/E
140%+Up 2%+₹556 Cr22.1
240%+Up 0–2%₹215 Cr22.2
340%+Flat₹16,144 Cr—
440%+Flat₹6,072 Cr48.0
540%+Flat₹40 Cr—
620–40%Up 2%+₹50,220 Cr43.8

Sign up free to see every company in the sector ranking and track IOL Chemicals.

Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology ranking

Financials of IOL Chemicals

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Financials of IOL Chemicals

Quarterly Results

Quarter-by-quarter operating performance

Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Sales +587563545520504502526523528552568580619
Expenses +491490481476454452484476465490510523527
Operating Profit96736444505142476362575793
OPM %16%13%12%9%10%10%8%9%12%11%10%10%15%
Other Income +97788764577-62
Interest5444324444343
Depreciation12141616161718191920202020
Profit before tax88625132383926284546412871
Tax %25%25%26%28%25%24%26%26%30%25%26%25%25%
Net Profit +65463823283019213234302153
EPS in Rs2.221.571.290.790.961.010.650.701.081.161.020.701.81

Financials of IOL Chemicals

Profit & Loss

Annual income statement trend

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Sales +3855807119831,6851,8941,9672,1842,2172,1332,0792,319
Expenses +3735296088631,2761,3211,3751,9271,9901,9011,8772,050
Operating Profit1151102120410574592257227232202269
OPM %3%9%14%12%24%30%30%12%10%11%10%12%
Other Income +11161016241725302210
Interest5961686451216816161515
Depreciation293030303236394346637280
Profit before tax-75-39631336533571223189183138184
Tax %-12%4%21%12%30%32%22%26%26%26%27%25%
Net Profit +-67-40528237361445166140135101138
EPS in Rs-2.80-1.420.170.998.3212.7015.155.644.774.613.444.69
Dividend Payout %0%0%0%0%0%5%8%14%17%22%23%21%

Financials of IOL Chemicals

Balance Sheet

Capital structure and asset base

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital485656565757595959595959
Reserves1601291321604177571,2021,3321,4481,5531,6291,740
Borrowings +400453447422284593448033117135
Other Liabilities +94135182214184297347526434600577653
Total Liabilities7027728178529421,1701,6101,9602,0212,2442,3822,587
Fixed Assets +4034003744064124695125617519331,1701,183
CWIP44217271948105901012294
Investments0000001220212121
Other Assets +2953694224395036821,0481,2921,1591,1901,1681,289
Total Assets7027728178529421,1701,6101,9602,0212,2442,3822,587

Financials of IOL Chemicals

Cash Flows

Operating, investing and financing cash movement

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity +-47188312027347138091123290179214
Cash from Investing Activity +-5-27-23-50-63-184-317-121-119-191-154-198
Cash from Financing Activity +509-60-70-197-272-58-2-4-9246-29
Net Cash Flow-2-01-113154-31-0770-13
Free Cash Flow-53-96171213391272-60-8618-3444
CFO/OP-413%34%82%105%83%102%88%60%75%144%97%94%

Financials of IOL Chemicals

Ratios

Working capital efficiency and return ratios

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days315558544352567983819095
Inventory Days27920120110966649895771119591
Days Payable92102115834262799574123112118
Cash Conversion Cycle218154144806755747986697368
Working Capital Days593936234346667172715853
ROCE %-3%4%12%15%56%68%54%18%14%12%9%11%

Guidance history

How IOL Chemicals's guidance has moved, call by call

CallRevenueMarginsCapexFundraisingOrder book
Q1 FY27 call →10–20%FlatPlanned—Rising
Q1 FY27 call →10–20%FlatPlanned—Rising
Q4 FY26 call →10–20%Up 0–2%PlannedNone planned—
Q3 FY26 call →10–20%Up 0–2%Planned——

What management guided on each call, newest first. Not investment advice, and not a forecast of returns.

94out of 100

Momentum score · price trend

94 out of 100 — Strengthening

Over the past year its share price has done better than most of the stocks we track.

PeriodShare price changeBetter than … of 1,910 stocks
Last 12 months+95.3%93%
Last 6 months+96.1%96%
Last 3 months+27.8%90%
How we calculate it

“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,910 Indian companies worth ₹500 Cr or more, with at least a year of prices).

The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For IOL Chemicals: 0.4 × 93 + 0.4 × 96 + 0.2 × 90 = 94.

Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.

Full methodology →

This describes only how the share price has moved up to 29 Oct 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.

Continue your research

What IOL Chemicals's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Lincoln Pharmaceuticals Ltd (Q2 FY27)

    2,798.12 Lakhs increase (approximately 17.1% growth) . Key results statement takeaways from Lincoln Pharmaceuticals Ltd's Q2 FY27 results statement — and how it

  • Alivus Life Sciences Ltd (Q2 FY27)

    Q2 FY27 Revenue from Operations: ₹6,820 million, up 16.0% year-on-year (YoY). Key investor presentation takeaways from Alivus Life Sciences Ltd's Q2 FY27 invest

  • Strides Pharma Science Ltd (Q2 FY27)

    Q2FY27 Revenue: ₹14,297 million, up 17.1% YoY (Page 4, 15) . Key investor presentation takeaways from Strides Pharma Science Ltd's Q2 FY27 investor presentation

  • Laurus Labs Ltd (Q2 FY27)

    2Q FY27 Revenue:** ₹2,206 crore, up 33% year-on-year (Y-o-Y) and 9% quarter-on-quarter (Q-o-Q). Key investor presentation takeaways from Laurus Labs Ltd's Q2 FY

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd